Sirexatamab (DKN-01)
– an anti-DKK1 antibody
Single agent and combination activity demonstrated in three different tumor types. Well tolerated as monotherapy and in combination with chemotherapy or checkpoint inhibitors.
Sirexatamab (DKN-01) binds and removes free DKK1 from the TME:
Reduces cell proliferation
Blocks signaling through CKAP4 and PI3K to downregulate Akt
Suppresses
MDSC cells
B-catenin dependent Wnt signaling reprograms MDSCs and reduces immunosuppressive activity
Reduces angiogenesis
Reduces blood vessel formation, upregulates key cytokines, IFNy, IL-15 and IL-33
Activates
NK cells
Upregulates NK cell ligands on tumor, production of Granzyme B by activated NK cells
DKK1 production from multiple sources can drive tumor growth
